BFM
CTXR icon

Boothbay Fund Management’s Citius Pharmaceuticals CTXR Stock Holding History

Boothbay Fund Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,008
Closed -$88K – 1901
2023
Q1 		$88K Buy
+3,008
New +$86.7K ﹤0.01% 1969
2022
Q3 		– Sell
-1,571
Closed -$36K – 2301
2022
Q2 		$36K Buy
+1,571
New +$43.1K ﹤0.01% 2117

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's CTXR Position: Q2 2023 in Review

Boothbay Fund Management sold out of Citius Pharmaceuticals (CTXR) in Q2 2023, closing a stake of 3,008 shares — an estimated $88K sold.

Boothbay Fund Management first reported a position in CTXR in Q2 2022 and held it in 2 quarters. The position peaked at $88K in Q1 2023. 74 funds tracked by Wall St. Rank hold CTXR as of Q2 2023.

  • Boothbay Fund Management reported no remaining Citius Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 3,008 Citius Pharmaceuticals shares in Q2 2023, an estimated $88K.
  • Boothbay Fund Management first reported a position in Citius Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Boothbay Fund Management's Citius Pharmaceuticals position peaked at $88K in Q1 2023.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.